FRM
BOLD

Fox Run Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Fox Run Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,443
Closed -$212K – 714
2019
Q1 		$212K Buy
+5,443
New +$156K 0.12% 375

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fox Run Management's BOLD Position: Q2 2019 in Review

Fox Run Management sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2019, closing a stake of 5,443 shares — an estimated $212K sold.

Fox Run Management first reported a position in BOLD in Q1 2019 and held it in 1 quarter. The position peaked at $212K in Q1 2019. 147 funds tracked by Wall St. Rank hold BOLD as of Q2 2019.

  • Fox Run Management reported no remaining Audentes Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Fox Run Management sold 5,443 Audentes Therapeutics, Inc shares in Q2 2019, an estimated $212K.
  • Fox Run Management first reported a position in Audentes Therapeutics, Inc in Q1 2019 and held it in 1 quarter.
  • Fox Run Management's Audentes Therapeutics, Inc position peaked at $212K in Q1 2019.
  • 147 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2019.

Based on Fox Run Management's 13F filing for Q2 2019, filed 17 Jul 2019.